Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Focus of Report: The focus of this Health Technology Assessment is to evaluate the effectiveness and safety of ultrasound-guided hydrodissection (HD) compared with alternative therapies for the treatment of carpal tunnel syndrome (CTS) in adults.
Technology Description: HD is a procedu…
Focus of the Report: The focus of this Health Technology Assessment is evaluation of the effectiveness and safety of wireless capsule endoscopy (WCE) compared with established techniques for diagnosis and guidance of the management of small and large bowel motility disorders.
Technology Descr…
This report evaluates the clinical utility of genetic testing for patients with clinically diagnosed autism spectrum disorder (ASD) and their first-degree relatives to determine genetic etiology, inform patient management, and improve outcomes.
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of body-contouring procedures in patients with gender dysphoria (GD).
Abrysvo (respiratory syncytial virus vaccine; Pfizer Inc.) is a vaccine indicated for active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
This report evaluates the clinical validity and clinical utility of the Cxbladder Detect test (Pacific Edge Ltd.).
The Spring Distraction System (Cresco Spine) is an investigational, growth-friendly implant in development for the treatment of early onset scoliosis (EOS). It is designed to provide continuous distraction and avoid the need for repeated lengthening procedures as the patient grows.
This report evaluates the clinical validity and clinical utility of the FoundationOne Heme test.
Palovarotene (Sohonos; Ipsen Biopharmaceuticals Inc.) is an oral retinoid indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for female persons and 10 years and older for male persons with fibrodysplasia ossificans progressiva.
Atidarsagene autotemcel is an investigational gene therapy administered by intravenous infusion for the treatment of metachromatic leukodystrophy.